FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3152423736> ?p ?o ?g. }

• W3152423736 endingPage "100123" @default.
• W3152423736 startingPage "100123" @default.
• W3152423736 abstract "•Synergistic COVID-19- and oncologic disease-mediated inflammation may drive mortality in patients with cancer and COVID-19.•Inflammation is not only a prognostic domain but also a source of therapeutic targets in patients with cancer and COVID-19.•Immunomodulatory drugs may benefit these patients through attenuation of the COVID-19-induced inflammatory state. Inflammation is an established driver of severe SARS-CoV-2 infection and a mechanism linked to the increased susceptibility to fatal COVID-19 demonstrated by patients with cancer. As patients with cancer exhibit a higher level of inflammation compared with the general patient population, patients with cancer and COVID-19 may uniquely benefit from strategies targeted at overcoming the unrestrained pro-inflammatory response. Targeted and non-targeted anti-inflammatory therapies may prevent end-organ damage in SARS-CoV-2-infected patients with cancer and decrease mortality. Here, we review the clinical role of selective inhibition of pro-inflammatory interleukins, tyrosine kinase modulation, anti-tumor necrosis factor agents, and other non-targeted approaches including corticosteroids in their roles as disease-modulating agents in patients with COVID-19 and cancer. Investigation of these therapeutics in this highly vulnerable patient group is posited to facilitate the development of tailored therapeutics for this patient population, aiding the transition of systemic inflammation from a prognostic domain to a source of therapeutic targets. Inflammation is an established driver of severe SARS-CoV-2 infection and a mechanism linked to the increased susceptibility to fatal COVID-19 demonstrated by patients with cancer. As patients with cancer exhibit a higher level of inflammation compared with the general patient population, patients with cancer and COVID-19 may uniquely benefit from strategies targeted at overcoming the unrestrained pro-inflammatory response. Targeted and non-targeted anti-inflammatory therapies may prevent end-organ damage in SARS-CoV-2-infected patients with cancer and decrease mortality. Here, we review the clinical role of selective inhibition of pro-inflammatory interleukins, tyrosine kinase modulation, anti-tumor necrosis factor agents, and other non-targeted approaches including corticosteroids in their roles as disease-modulating agents in patients with COVID-19 and cancer. Investigation of these therapeutics in this highly vulnerable patient group is posited to facilitate the development of tailored therapeutics for this patient population, aiding the transition of systemic inflammation from a prognostic domain to a source of therapeutic targets." @default.
• W3152423736 created "2021-04-13" @default.
• W3152423736 creator A5001343667 @default.
• W3152423736 creator A5015437737 @default.
• W3152423736 creator A5038933116 @default.
• W3152423736 creator A5045454738 @default.
• W3152423736 creator A5060954139 @default.
• W3152423736 creator A5078846012 @default.
• W3152423736 creator A5076627681 @default.
• W3152423736 date "2021-06-01" @default.
• W3152423736 modified "2023-10-09" @default.
• W3152423736 title "The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer" @default.
• W3152423736 cites W1153335416 @default.
• W3152423736 cites W1483308173 @default.
• W3152423736 cites W1540592014 @default.
• W3152423736 cites W1672748625 @default.
• W3152423736 cites W184388943 @default.
• W3152423736 cites W1883475886 @default.
• W3152423736 cites W1915758749 @default.
• W3152423736 cites W1965037168 @default.
• W3152423736 cites W1974554594 @default.
• W3152423736 cites W2001089941 @default.
• W3152423736 cites W2001627013 @default.
• W3152423736 cites W2009114635 @default.
• W3152423736 cites W2014229457 @default.
• W3152423736 cites W2019750642 @default.
• W3152423736 cites W2033023829 @default.
• W3152423736 cites W2034269086 @default.
• W3152423736 cites W2036285678 @default.
• W3152423736 cites W2037418955 @default.
• W3152423736 cites W2045352639 @default.
• W3152423736 cites W2046776183 @default.
• W3152423736 cites W2057000045 @default.
• W3152423736 cites W2058788010 @default.
• W3152423736 cites W2063209691 @default.
• W3152423736 cites W2064343277 @default.
• W3152423736 cites W2114794962 @default.
• W3152423736 cites W2123105952 @default.
• W3152423736 cites W2131930163 @default.
• W3152423736 cites W2133367456 @default.
• W3152423736 cites W2135137305 @default.
• W3152423736 cites W2138163679 @default.
• W3152423736 cites W2140500533 @default.
• W3152423736 cites W2148658155 @default.
• W3152423736 cites W2150472441 @default.
• W3152423736 cites W2166650533 @default.
• W3152423736 cites W2172081252 @default.
• W3152423736 cites W2180085345 @default.
• W3152423736 cites W2340435799 @default.
• W3152423736 cites W2408097265 @default.
• W3152423736 cites W2510987450 @default.
• W3152423736 cites W2545892249 @default.
• W3152423736 cites W2576634593 @default.
• W3152423736 cites W2594667125 @default.
• W3152423736 cites W2604499737 @default.
• W3152423736 cites W2750906538 @default.
• W3152423736 cites W2766225245 @default.
• W3152423736 cites W2772666421 @default.
• W3152423736 cites W2791299132 @default.
• W3152423736 cites W2796022095 @default.
• W3152423736 cites W2800246801 @default.
• W3152423736 cites W2804035619 @default.
• W3152423736 cites W2810896552 @default.
• W3152423736 cites W2811431973 @default.
• W3152423736 cites W2884091495 @default.
• W3152423736 cites W2887920184 @default.
• W3152423736 cites W2888716586 @default.
• W3152423736 cites W2901171191 @default.
• W3152423736 cites W2924154682 @default.
• W3152423736 cites W2936183454 @default.
• W3152423736 cites W2946882253 @default.
• W3152423736 cites W2947436713 @default.
• W3152423736 cites W2954782052 @default.
• W3152423736 cites W2971774950 @default.
• W3152423736 cites W2973019461 @default.
• W3152423736 cites W2981750308 @default.
• W3152423736 cites W3004709581 @default.
• W3152423736 cites W3006138994 @default.
• W3152423736 cites W3010839841 @default.
• W3152423736 cites W3013824109 @default.
• W3152423736 cites W3014050022 @default.
• W3152423736 cites W3014972620 @default.
• W3152423736 cites W3016126001 @default.
• W3152423736 cites W3016661132 @default.
• W3152423736 cites W3016667495 @default.
• W3152423736 cites W3016852213 @default.
• W3152423736 cites W3017340845 @default.
• W3152423736 cites W3018517500 @default.
• W3152423736 cites W3020710323 @default.
• W3152423736 cites W3021270571 @default.
• W3152423736 cites W3021389063 @default.
• W3152423736 cites W3021391038 @default.
• W3152423736 cites W3022358203 @default.
• W3152423736 cites W3023007524 @default.
• W3152423736 cites W3023189656 @default.
• W3152423736 cites W3023982717 @default.
• W3152423736 cites W3024048796 @default.
• W3152423736 cites W3026319320 @default.

• next